DNA Pharma Companies Small Molecule 
Drug Discovery World
SEPTEMBER 29, 2022
The company has the resources to complete the project in-house or it could outsource it to CROs. The company has narrowed down their decision to three options: Option #1: Company Z performs the project internally and screens their in-house collection of 250,000 small molecules using a traditional fluorescence-based biochemical assay.
DrugBaron
FEBRUARY 7, 2022
Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 3, 2023
Matthew Clark , CEO of X-Chem, looks at what the future could hold for DNA-encoded library (DEL) technology. In the 13 years since it was first described, DNA-encoded library (DEL) technology has become a firmly established approach to small molecule hit generation in drug discovery. Artificial intelligence. Wu Z, et al.
DrugBaron
JULY 19, 2022
Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. It has a vibrant community of life-science companies, from global pharma to smaller start-ups.
Drug Discovery World
NOVEMBER 15, 2022
Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .
Drug Discovery World
OCTOBER 7, 2022
TH : Increasingly, large pharma companies need scale, agility and access to academic partnerships to succeed. It is unsurprising that many pharma companies are increasingly keen to work with academia or academic spin-out. companies to supplement their own R&D; most novel ideas stem from academia. Tony Hickson.
Expert insights. Personalized for you.
130 
Let's personalize your content